NewAmsterdam Pharma to Present at a Major Biotech Conference
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), a forward-thinking biopharmaceutical organization, is preparing to participate in an important event aimed at advancing discussions around innovative therapeutic solutions for cardiovascular disease. The Chief Financial Officer, Ian Somaiya, will represent the company in a significant fireside chat scheduled for an upcoming date at the Guggenheim SMID Cap Biotech Conference.
Transformative Developments in Cardiovascular Care
As a late-stage clinical biopharmaceutical company, NewAmsterdam is dedicated to the development of oral, non-statin medicines targeting patients who are at an increased risk of cardiovascular disease (CVD). With a mission built on improving patient outcomes, the company has prioritized the creation of therapies that address the challenges posed by elevated low-density lipoprotein cholesterol (LDL-C). Traditional therapies often fall short, creating a pressing need for more effective and better-tolerated treatments.
About NewAmsterdam Pharma's Innovative Approaches
NewAmsterdam Pharma focuses on filling crucial gaps in the treatment landscape for metabolic diseases. Their leading candidate, obicetrapib, stands out as an oral, low-dose, once-daily CETP inhibitor. This drug is being evaluated in multiple phase 3 trials, both as a standalone therapy and in combination with ezetimibe. The goal is to provide a robust solution for patients not effectively managed by current treatments.
Building on Clinical Evidence
The ongoing studies aim to demonstrate that obicetrapib can substantially lower LDL-C levels, making it a viable adjunct therapy for patients who may require additional support alongside statin medications. This innovative approach underscores NewAmsterdam’s commitment to not only addressing immediate medical needs but also elevating standards of care in cardiovascular health.
Engagement and Outreach
To ensure continuous communication with stakeholders and the public, NewAmsterdam will host a live webcast of the fireside chat, providing insight into their strategic vision and upcoming developments. An archived replay will also be readily accessible for anyone who wishes to revisit the discussion at a later time.
Contacting NewAmsterdam Pharma
For inquiries, NewAmsterdam encourages stakeholders to contact their representative Matthew Philippe at 1-917-882-7512 or via email. Additionally, for media-related questions, Jaryd Leady from Spectrum Science is available at 1-856-803-7855.
Frequently Asked Questions
What is the main focus of NewAmsterdam Pharma?
NewAmsterdam Pharma is centered around developing oral, non-statin medicines for patients at risk of cardiovascular disease and high LDL cholesterol.
Who will represent NewAmsterdam at the conference?
Ian Somaiya, the Chief Financial Officer, will represent NewAmsterdam Pharma during the fireside chat at the Guggenheim conference.
What is obicetrapib and its significance?
Obicetrapib is a CETP inhibitor in phase 3 trials, intended to lower LDL cholesterol levels and enhance patient care for those with cardiovascular risks.
How can one access the fireside chat?
The fireside chat will be available through the investor relations section of the NewAmsterdam Pharma website, with an archived version post-event.
How can I reach NewAmsterdam for inquiries?
For questions, contact Matthew Philippe at 1-917-882-7512 or email. Media inquiries can be directed to Jaryd Leady at 1-856-803-7855.
